Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Monopar Therapeutics presented new analyses from the Phase 3 FoCus trial at EAN 2026, showing that ALXN1840 delivered significant neurologic improvement and greater global clinical benefit compared to standard of care in Wilson disease patients. Data from a subset of 207 patients showed statistically significant improvements on key rating scales for ALXN1840 (p=0.006 for neurologic improvement), whereas standard of care did not achieve significance.
Key figures
- Drug Name
- ALXN1840 (tiomolibdate choline, TMC)
- Phase Of Trial
- Phase 3
- Cgi i p value
- <0.001
- Study population
- 207
- Safety population
- 266
- Neurologic sae percent
- < 1
- Uwdrs part iii p value
- 0.006
- Drug related saes percent
- 4.9
- Median treatment duration years
- 2.58
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.